Take a look at some of the biggest movers in the premarket:

CureVac (CVAC) – CureVac shares plunged 46.2% in the premarket after the German drugmaker reported disappointing results from a study of its experimental Covid-19 vaccine. The treatment was 47% effective in a clinical trial, compared to more than 90% for other mRNA-based vaccines from Moderna (MRNA) and Pfizer (PFE).